Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATB200 with AT2221 in adults with Pompe disease
NL-OMON50710Phase 2Active, not recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Nov 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cipaglucosidase alfa and miglustat in Pompe disease, sponsored by Amicus Therapeutics. Started Nov 2016; status: active, not recruiting.
02
Drugs
cipaglucosidase alfamiglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON50710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50710.